dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Pavel, Marianne E. |
dc.contributor.author | Ćwikła, Jarosław B. |
dc.contributor.author | Lombard-Bohas, Catherine |
dc.contributor.author | Shah, Tahir |
dc.contributor.author | Pape, Ulrich F. |
dc.contributor.author | Capdevila Castillon, Jaume |
dc.contributor.author | Borbath, Ivan |
dc.date.accessioned | 2022-07-18T12:32:56Z |
dc.date.available | 2022-07-18T12:32:56Z |
dc.date.issued | 2021-11 |
dc.identifier.citation | Pavel M, Ćwikła JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, et al. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. Eur J Cancer. 2021 Nov;157:403–14. |
dc.identifier.issn | 0959-8049 |
dc.identifier.uri | https://hdl.handle.net/11351/7791 |
dc.description | Lanreòtid; Supervivència lliure de progressió; Somatostatina |
dc.description.sponsorship | This study was sponsored by Ipsen. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | European Journal of Cancer;157 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Tumors neuroendocrins - Tractament |
dc.subject | Posologia |
dc.subject.mesh | Neuroendocrine Tumors |
dc.subject.mesh | /drug therapy |
dc.title | Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.ejca.2021.06.056 |
dc.subject.decs | tumores neuroendocrinos |
dc.subject.decs | /farmacoterapia |
dc.relation.publishversion | https://doi.org/10.1016/j.ejca.2021.06.056 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Pavel M] Department of Medicine 1, Friedrich Alexander University Erlangen-Nürnberg, Erlangen, Germany. [Ćwikła JB] University of Warmia and Mazury, Olsztyn, Poland; Diagnostic and Therapeutic Center – Gammed, Warsaw, Poland. [Lombard-Bohas C] Edouard-Herriot Hospital, HCL Cancer Institute, Lyon, France. [Borbath I] Cliniques Universitaires Saint-Luc, Brussels, Belgium. [Shah T] Queen Elizabeth Hospital Birmingham, Birmingham, UK. [Pape UF] Charité – Universitätsmedizin Berlin, Berlin, Germany. Asklepios Klinik St Georg, Asklepios Tumourzentrum Hamburg, Asklepios Medical School, Hamburg, Germany. [Capdevila J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 34597974 |
dc.identifier.wos | 000708717900002 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |